Preeti Narayan
3PUBLICATIONS
21CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Aug 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Suparna Wedam, Preeti Narayan, Haley Gittleman
|Aug 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment Setting.Jennifer J Gao, Tatiana M Prowell, Haley Gittleman
|Feb 13, 2023
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer.Preeti Narayan, Asma Dilawari, Christy Osgood
Pageof 1
Frequent Collaborators
3 joint publications
William Pierce
3 joint publications
Shenghui Tang
3 joint publications
Richard Pazdur
3 joint publications
Laleh Amiri-Kordestani
2 joint publications
Vishal Bhatnagar
2 joint publications
Haley Gittleman
1 joint publications
Asma Dilawari
1 joint publications
Zhou Feng
1 joint publications
Erik Bloomquist
1 joint publications
Samina Jafri
